Fundz

Fundz Deep Dive

Everything you need to win Innovent Biologics (Innovent) — in one platform.

Who to reach, what to say, and why now on Innovent Biologics (Innovent) — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Innovent Biologics (Innovent) — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Innovent and Lilly Expand Collaboration Through Distribution and Promotion Agreement on Commercialization Rights for Jaypirca® (pirtobrutinib) in Mainland China

Dec 16, 2024•over 1 year ago

Contract Type

agreement

ManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Innovent Biologics, Inc. and Eli Lilly and Company have announced a Distribution and Promotion Agreement in Mainland China regarding Lilly's non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, Jaypirca® (pirtobrutinib, 100 mg & 50 mg tablets). The agreement aims to promote and distribute Jaypirca® in Mainland China for the treatment of mantle cell lymphoma (MCL) patients, addressing the unmet clinical needs for these patients.

Company Information

Company

Innovent Biologics (Innovent)

About

Innovent Biologics, Inc. (Innovent) is a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases.

Predictive Intelligence
Strategic

ML-powered predictions for Innovent Biologics (Innovent)'s next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.